Greece Pharmaceuticals and Healthcare Q3 2012

Date: July 17, 2012
Pages: 93
US$ 1,295.00
Report type: Strategic Report
Delivery: E-mail Delivery (PDF), Download
ID: G9FD4131811EN

Download PDF Leaflet

Includes 3 FREE quarterly updates

BMI View: Following weeks of speculation and apocalyptic warnings of a potential exit from the eurozone, Greek elections have yielded a much more benign outcome than many feared. The electoral result had huge implications for our assessment of the pharmaceutical and healthcare market, as this vote was widely seen as a proxy vote of eurozone membership. Following the result, we maintain our core forecast scenario of continued austerity. Indicators that Germany and the rest of the EU may reduce the focus on austerity and introduce some pro-growth driven strategies are unlikely to represent any upside for the pharmaceutical industry and the structural reforms within Greece will be maintained.

Headline Expenditure Projections
  • Pharmaceuticals: EUR6.72bn (US$9.35bn) in 2011 to EUR5.92bn (US$7.64bn) in 2012; -11.9% in local currency terms and -18.3% in US dollar terms. Forecast maintained from Q212.
  • Healthcare: EUR21.80bn (US$30.31bn) in 2011 to EUR20.28bn (US$26.16bn) in 2012; -7.0% in local currency terms and -13.7% in US dollar terms. Forecast lowered from Q212 due to new industry factors and macroeconomic indicators.
  • Medical devices: EUR670mn (US$931mn) in 2011 to EU607mn (US$783mn) in 2012; -9.3% in local currency terms and -15.9% in US dollar terms. Forecast down significantly from Q212 due to industry and macroeconomic factors and revised 2011 medical device calculations. Risk/Reward Rating: Our assessment of Greece’s pharmaceutical market has declined again, with a further downward revision to the industry risk score in our Q312 Pharmaceutical Risk/Reward Ratings (RRRs) for the region. Our view that Greece’s pharmaceutical market is set for a decade of decline remains firmly in play and its leading position in our Central and Eastern Europe (CEE) RRRs in 2009 seems a distant memory.
Key Views On Market Dynamics
  • Drugmakers will not withdraw existing products from Greece but they will increase the conditions for their sale. We do not believe multinational drugmakers will see it as necessary to withdraw large swathes of their product portfolios from the market and even after a eurozone exit they would make the necessary preparations to supply the market with critical drugs, even without clear payment terms.
  • Ignoring the moral obligations, it makes commercial sense for drugmakers to stick it out in Greece. Even if there are immediate costs and even if the Greek drug market never recovers, the global implications and negative headlines of pulling ‘life-saving medicines from a people in crises’ are surely worse.
  • Drugmakers must now consider Greece on the same terms as other less-advanced South Eastern European markets.
  • This year is considerably worse than 2011. The challenges facing drugmakers in Greece in 2012 are considerably tougher than those faced in 2011. Under the new cost-containment legislation introduced in March, the government can now exercise much greater control over the pharmaceutical budget.
  • Low budgets are insufficient. Despite promises that the National Organisation for Health Services (EOPYY) would settle unpaid drugs bills owed to pharmacists and accrued in the first few months of this year, without additional resources for reimbursement these payments are unsustainable.
  • Medicine shortages are already a problem. There are reportedly 163 essential medicines that are unavailable from pharmacies in Greece.
  • Fears about medicines shortages have grown in the last few months. Unpaid drug bills for pharmacists and delays in payments to pharmacists are exacerbating late payments to drugmakers further up the supply chain.
BMI Economic View: The Greek economy will remain mired in depression through 2012 as deep fiscal retrenchment and internal devaluation take a damaging toll.

The prospect of further spending cuts and tax hikes will ensure that demonstrations and national strikes remain a key feature of the political landscape over the medium term. Internal devaluation will be a slow and drawn-out process, which will ensure that the current account deficit will narrow only gradually, keeping pressure on foreign financing over the medium term.

BMI Political View: Following weeks of speculation and apocalyptic warnings of a potential exit from the eurozone, Greek elections have yielded a much more benign outcome than many feared. New Democracy picked up more votes since the election and will has formed a new government. Despite some potentially minor concessions in the short term, the incoming government will continue to follow the austerity path prescribed by the troika. This in turn will fuel social tensions and motivate some party members to defect, which would reduce the government’s majority in parliament. As such, more elections remain a possibility. Ultimately, however, we still expect Germany to relent on blunt austerity and opt for a more balanced deficit reduction and growth path. This could be a year or more away, with turmoil in Greece persisting in the meantime.
Executive Summary
SWOT Analysis
Greece Pharmaceuticals And Healthcare Industry SWOT
Greece Political SWOT
Greece Economic SWOT
Greece Business Environment SWOT
Pharmaceutical Risk/Reward Ratings
  Table: Central And Eastern Europe Pharmaceutical Risk/Reward Ratings, Q312
Greece - Market Summary
Regional Strategy
Regulatory Regime
Intellectual Property Regime
Pricing Regime
  Table: Quarterly Total Sales Volume Per Medicinal Product (additional to 9% of the current decision rebate amount)
Drug Price Deflation
Reimbursement Regime
Industry Developments
Healthcare System
Hospital Sector Debt Affecting Drugmakers
Industry Forecast Scenario
Overall Market Forecast
  Table: Pharmaceutical Sales, 2008-2016
Alternative Scenario: Implications Of A Euro Exit On The Greek Drug Market
Key Growth Factors – Healthcare
  Table: Overall Healthcare Expenditure, 2008-2016
  Table: Government Healthcare Expenditure, 2008-2016
  Table: Private Healthcare Expenditure, 2008-2016
Key Growth Factors – Macroeconomic
  Table: Greece Core Macroeconomic Forecasts, 2010-2016
Prescription Drug Market Forecast
  Table: Prescription Drug Sales, 2008-2016
Patented Drug Market Forecast
  Table: Patented Drug Sales, 2008-2016
Generic Drug Market Forecast
  Table: Generic Drug Sales, 2008-2016
OTC Medicine Market Forecast
  Table: OTC Medicine Sales, 2008-2016
  Table: OTC Medicine Sales Breakdown, 2007-2010
Pharmaceutical Trade Forecast
Greece Pharmaceuticals & Healthcare Report Q3 2012
© Business Monitor International Ltd Page
  Table: Pharmaceutical Trade, 2008-2016
Medical Device Market Forecast
  Table: Medical Device Sales, 2008-2016
Key Risks To BMI’s Forecasts
Competitive Landscape
Company Activity
Company Profiles
Local Company Profiles
Genesis Pharma
Pharmathen Pharmaceuticals
Alapis Pharma
Multinational Companies
Merck Sharp & Dohme
Abbott Laboratories
Demographic Outlook
  Table: Population By Age Group, 1990-2020 (‘000)
  Table: Population By Age Group, 1990-2020 (% of total)
  Table: Greece’s Key Population Ratios, 1990-2020
  Table: Rural/Urban Population Split, 1990-2020
BMI Methodology
How We Generate Our Pharmaceutical Industry Forecasts
Pharmaceuticals Risk/Reward Ratings Methodology
Ratings Overview
  Table: Pharmaceutical Risk/Reward Indicators
  Table: Weighting Of Components
Skip to top

Ask Your Question

Greece Pharmaceuticals and Healthcare Q3 2012
Company name*:
Contact person*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: